Jasper Therapeutics announced that four abstracts featuring its investigational therapy briquilimab have been accepted for presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, scheduled for June 13-16, 2025 in Glasgow, United Kingdom. The presentations will showcase initial clinical data from the company's ongoing SPOTLIGHT Phase 1b/2a study and preclinical research supporting the drug's mechanism of action.
Clinical Data from SPOTLIGHT Study
The company will present initial clinical data from patients enrolled in the 180mg cohort of the SPOTLIGHT Phase 1b/2a dose escalation study during an oral session on June 14. This study evaluates subcutaneous briquilimab in adults with chronic inducible urticaria (CIndU), specifically cold urticaria (ColdU) or symptomatic dermographism (SD), who remain symptomatic despite H-1 antihistamine treatment.
The oral presentation, titled "Initial Results from SPOTLIGHT, a Phase 1b/2a Dose Escalation Study of the anti-c-Kit Briquilimab Antibody in Adults with Inducible Urticaria (CIndU) Who Remain Symptomatic Despite H-1 Antihistamine Treatment," will be delivered during the Clinical Trials on Dermatology session from 3:00-4:30pm.
Chronic Spontaneous Urticaria Results
Additional clinical data will be presented in a flash talk session focusing on chronic spontaneous urticaria (CSU). The presentation, "Briquilimab Demonstrates Rapid, Clinically Meaningful Disease-Control in Adults with Chronic Spontaneous Urticaria (CSU): Updated Results from Phase 1b/2a Study," will showcase updated results from the company's Phase 1b/2a study on June 15 from 12:45-1:45pm.
Preclinical Research Presentations
Two poster presentations will detail preclinical research supporting briquilimab's therapeutic potential. One study demonstrates that a single dose of briquilimab protects against relapse of epicutaneous allergen-induced dermatitis in mice expressing chimeric human/mouse CD117. The second preclinical presentation shows that targeting mast cells with briquilimab mitigates COPD-like features in an allergen and cigarette smoke-exacerbated asthma model using humanized mice.
Mechanism of Action and Therapeutic Approach
Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor KIT (CD117). This inhibition disrupts the critical survival signal, leading to the depletion of mast cells via apoptosis, which removes the underlying source of the inflammatory response in mast cell-driven diseases such as chronic urticaria and asthma.
According to Jasper Therapeutics, briquilimab has demonstrated efficacy and safety profile in patients and healthy volunteers, with positive clinical outcomes in CSU and CIndU. The company is currently conducting clinical studies of briquilimab as a treatment in patients with CSU, CIndU, and asthma.
Company Focus and Development Pipeline
Jasper Therapeutics is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. The company's approach targets the c-Kit receptor to address mast cell-driven diseases including chronic spontaneous urticaria, chronic inducible urticaria, and asthma.
